Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Study 2 was a 68-week trial that enrolled 1,961 patients with obesity (BMI greater than or equal to 30 kg/m2) or with overweight (BMI 27 to 29.9 kg/m2) and at least one weight-related comorbid condition, such as treated or untreated dyslipidemia or hypertension
Remember to celebrate your progress and persevereyour health is an investment worth making
So the phase 3a trials that supported the approval of semaglutide for the treatment of obesity
AACE Patient Guide to Metabolic DysfunctionAssociated Steatotic Liver Disease (MASLD) and Metabolic DysfunctionAssociated Steatohepatitis (MASH)
For your safety and comfort, our experienced medical team will guide you on how to rotate your injection sites with each dose to minimize the risk of skin irritation or lipodystrophy
